IRF3 and neoplasm: Upon release inside the tumor microenvironment, these payloads activate the STING pathway in tumor and immune cells, triggering a signaling cascade that culminates in the phosphorylation of TBK1 and IRF3, resulting in robust type I interferon production and pro-inflammatory cytokine secretion.